SHANGHAI & INDIANAPOLIS--(BUSINESS WIRE)--Acerand Therapeutics, a clinical-stage biotechnology company focused on developing innovative therapies in oncology, metabolic diseases, and immunology, today ...
Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors Acerand Therapeutics Reports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results